nodes	percent_of_prediction	percent_of_DWPC	metapath
Bosentan—ABCB11—Doxorubicin—urinary bladder cancer	0.166	0.42	CbGbCtD
Bosentan—CYP3A4—Thiotepa—urinary bladder cancer	0.0922	0.233	CbGbCtD
Bosentan—CYP2C9—Fluorouracil—urinary bladder cancer	0.0515	0.13	CbGbCtD
Bosentan—CYP2C9—Cisplatin—urinary bladder cancer	0.0437	0.111	CbGbCtD
Bosentan—CYP3A4—Etoposide—urinary bladder cancer	0.025	0.0632	CbGbCtD
Bosentan—CYP3A4—Doxorubicin—urinary bladder cancer	0.017	0.0431	CbGbCtD
Bosentan—EDNRB—prostate gland—urinary bladder cancer	0.011	0.143	CbGeAlD
Bosentan—EDNRA—prostate gland—urinary bladder cancer	0.00911	0.118	CbGeAlD
Bosentan—CYP2C9—urine—urinary bladder cancer	0.00839	0.109	CbGeAlD
Bosentan—EDNRA—seminal vesicle—urinary bladder cancer	0.0077	0.1	CbGeAlD
Bosentan—EDNRB—urethra—urinary bladder cancer	0.00738	0.0959	CbGeAlD
Bosentan—CYP3A4—urine—urinary bladder cancer	0.0064	0.0832	CbGeAlD
Bosentan—EDNRA—urethra—urinary bladder cancer	0.0061	0.0793	CbGeAlD
Bosentan—EDNRB—vagina—urinary bladder cancer	0.00544	0.0707	CbGeAlD
Bosentan—EDNRA—vagina—urinary bladder cancer	0.0045	0.0584	CbGeAlD
Bosentan—EDNRB—lymph node—urinary bladder cancer	0.00352	0.0457	CbGeAlD
Bosentan—EDNRA—lymph node—urinary bladder cancer	0.00291	0.0378	CbGeAlD
Bosentan—CYP2C9—female reproductive system—urinary bladder cancer	0.00164	0.0214	CbGeAlD
Bosentan—CYP3A4—renal system—urinary bladder cancer	0.00157	0.0204	CbGeAlD
Bosentan—CYP3A4—female reproductive system—urinary bladder cancer	0.00125	0.0163	CbGeAlD
Bosentan—EDNRA—EGFR-dependent Endothelin signaling events—EGFR—urinary bladder cancer	0.00114	0.0366	CbGpPWpGaD
Bosentan—CYP2C9—Tamoxifen metabolism—UGT2B7—urinary bladder cancer	0.00105	0.0338	CbGpPWpGaD
Bosentan—EDNRA—EGFR-dependent Endothelin signaling events—HRAS—urinary bladder cancer	0.000917	0.0294	CbGpPWpGaD
Bosentan—EDNRB—Prostaglandin Synthesis and Regulation—PTGS2—urinary bladder cancer	0.000859	0.0276	CbGpPWpGaD
Bosentan—CYP2C9—Oxidation by Cytochrome P450—POR—urinary bladder cancer	0.000856	0.0275	CbGpPWpGaD
Bosentan—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—urinary bladder cancer	0.000818	0.0262	CbGpPWpGaD
Bosentan—CYP3A4—Estrogen metabolism—UGT2B7—urinary bladder cancer	0.000787	0.0253	CbGpPWpGaD
Bosentan—CYP3A4—Tamoxifen metabolism—UGT2B7—urinary bladder cancer	0.000696	0.0223	CbGpPWpGaD
Bosentan—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP4B1—urinary bladder cancer	0.000646	0.0207	CbGpPWpGaD
Bosentan—EDNRA—Prostaglandin Synthesis and Regulation—PTGS2—urinary bladder cancer	0.000615	0.0197	CbGpPWpGaD
Bosentan—CYP3A4—Oxidation by Cytochrome P450—POR—urinary bladder cancer	0.000564	0.0181	CbGpPWpGaD
Bosentan—EDNRB—Endothelins—RHOA—urinary bladder cancer	0.000524	0.0168	CbGpPWpGaD
Bosentan—CYP3A4—Aflatoxin B1 metabolism—GSTM1—urinary bladder cancer	0.000496	0.0159	CbGpPWpGaD
Bosentan—CYP2C9—Arachidonic acid metabolism—CYP4B1—urinary bladder cancer	0.000474	0.0152	CbGpPWpGaD
Bosentan—ABCB11—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000456	0.0146	CbGpPWpGaD
Bosentan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP4B1—urinary bladder cancer	0.000426	0.0137	CbGpPWpGaD
Bosentan—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.00041	0.0132	CbGpPWpGaD
Bosentan—CYP2C9—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.000405	0.013	CbGpPWpGaD
Bosentan—EDNRB—Endothelins—SRC—urinary bladder cancer	0.000384	0.0123	CbGpPWpGaD
Bosentan—EDNRA—Endothelins—RHOA—urinary bladder cancer	0.000375	0.012	CbGpPWpGaD
Bosentan—CYP2C9—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.000332	0.0107	CbGpPWpGaD
Bosentan—CYP2C9—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.000331	0.0106	CbGpPWpGaD
Bosentan—CYP3A4—Estrogen metabolism—NQO1—urinary bladder cancer	0.000304	0.00975	CbGpPWpGaD
Bosentan—Weight decreased—Doxorubicin—urinary bladder cancer	0.000292	0.000587	CcSEcCtD
Bosentan—Sinusitis—Epirubicin—urinary bladder cancer	0.000291	0.000587	CcSEcCtD
Bosentan—Hyperglycaemia—Doxorubicin—urinary bladder cancer	0.000291	0.000586	CcSEcCtD
Bosentan—Pneumonia—Doxorubicin—urinary bladder cancer	0.000289	0.000582	CcSEcCtD
Bosentan—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000289	0.000582	CcSEcCtD
Bosentan—Pruritus—Fluorouracil—urinary bladder cancer	0.000288	0.00058	CcSEcCtD
Bosentan—Infestation NOS—Doxorubicin—urinary bladder cancer	0.000287	0.000579	CcSEcCtD
Bosentan—Infestation—Doxorubicin—urinary bladder cancer	0.000287	0.000579	CcSEcCtD
Bosentan—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	0.000285	0.000574	CcSEcCtD
Bosentan—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000284	0.000572	CcSEcCtD
Bosentan—Bradycardia—Epirubicin—urinary bladder cancer	0.000284	0.000572	CcSEcCtD
Bosentan—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000283	0.00057	CcSEcCtD
Bosentan—Renal failure—Doxorubicin—urinary bladder cancer	0.000283	0.000569	CcSEcCtD
Bosentan—Erythema multiforme—Methotrexate—urinary bladder cancer	0.000282	0.000567	CcSEcCtD
Bosentan—Urticaria—Etoposide—urinary bladder cancer	0.000281	0.000566	CcSEcCtD
Bosentan—Haemoglobin—Epirubicin—urinary bladder cancer	0.00028	0.000565	CcSEcCtD
Bosentan—Stomatitis—Doxorubicin—urinary bladder cancer	0.00028	0.000564	CcSEcCtD
Bosentan—Jaundice—Doxorubicin—urinary bladder cancer	0.00028	0.000564	CcSEcCtD
Bosentan—Abdominal pain—Etoposide—urinary bladder cancer	0.000279	0.000563	CcSEcCtD
Bosentan—Body temperature increased—Etoposide—urinary bladder cancer	0.000279	0.000563	CcSEcCtD
Bosentan—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.000279	0.000563	CcSEcCtD
Bosentan—Conjunctivitis—Doxorubicin—urinary bladder cancer	0.000279	0.000563	CcSEcCtD
Bosentan—Haemorrhage—Epirubicin—urinary bladder cancer	0.000279	0.000562	CcSEcCtD
Bosentan—Hepatitis—Epirubicin—urinary bladder cancer	0.000279	0.000562	CcSEcCtD
Bosentan—Eye disorder—Methotrexate—urinary bladder cancer	0.000278	0.000561	CcSEcCtD
Bosentan—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000278	0.000561	CcSEcCtD
Bosentan—Tinnitus—Methotrexate—urinary bladder cancer	0.000278	0.00056	CcSEcCtD
Bosentan—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.000277	0.000559	CcSEcCtD
Bosentan—Asthenia—Cisplatin—urinary bladder cancer	0.000277	0.000558	CcSEcCtD
Bosentan—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000277	0.000557	CcSEcCtD
Bosentan—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000275	0.000555	CcSEcCtD
Bosentan—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000275	0.000553	CcSEcCtD
Bosentan—EDNRA—Endothelins—SRC—urinary bladder cancer	0.000275	0.00881	CbGpPWpGaD
Bosentan—Haematuria—Doxorubicin—urinary bladder cancer	0.000274	0.000552	CcSEcCtD
Bosentan—Urethral disorder—Epirubicin—urinary bladder cancer	0.000273	0.000551	CcSEcCtD
Bosentan—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.000272	0.000548	CcSEcCtD
Bosentan—Epistaxis—Doxorubicin—urinary bladder cancer	0.000271	0.000546	CcSEcCtD
Bosentan—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.00027	0.00868	CbGpPWpGaD
Bosentan—Angiopathy—Methotrexate—urinary bladder cancer	0.00027	0.000545	CcSEcCtD
Bosentan—EDNRB—Endothelins—HRAS—urinary bladder cancer	0.00027	0.00867	CbGpPWpGaD
Bosentan—Sinusitis—Doxorubicin—urinary bladder cancer	0.00027	0.000543	CcSEcCtD
Bosentan—Immune system disorder—Methotrexate—urinary bladder cancer	0.000269	0.000542	CcSEcCtD
Bosentan—Dizziness—Fluorouracil—urinary bladder cancer	0.000269	0.000542	CcSEcCtD
Bosentan—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000269	0.000541	CcSEcCtD
Bosentan—Chills—Methotrexate—urinary bladder cancer	0.000267	0.000539	CcSEcCtD
Bosentan—CYP3A4—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.000267	0.00856	CbGpPWpGaD
Bosentan—Diarrhoea—Cisplatin—urinary bladder cancer	0.000264	0.000532	CcSEcCtD
Bosentan—Erythema multiforme—Epirubicin—urinary bladder cancer	0.000264	0.000531	CcSEcCtD
Bosentan—Vomiting—Gemcitabine—urinary bladder cancer	0.000263	0.00053	CcSEcCtD
Bosentan—Bradycardia—Doxorubicin—urinary bladder cancer	0.000263	0.000529	CcSEcCtD
Bosentan—Mental disorder—Methotrexate—urinary bladder cancer	0.000261	0.000526	CcSEcCtD
Bosentan—Rash—Gemcitabine—urinary bladder cancer	0.000261	0.000526	CcSEcCtD
Bosentan—Dermatitis—Gemcitabine—urinary bladder cancer	0.000261	0.000525	CcSEcCtD
Bosentan—Eye disorder—Epirubicin—urinary bladder cancer	0.000261	0.000525	CcSEcCtD
Bosentan—Hypersensitivity—Etoposide—urinary bladder cancer	0.00026	0.000524	CcSEcCtD
Bosentan—Tinnitus—Epirubicin—urinary bladder cancer	0.00026	0.000524	CcSEcCtD
Bosentan—Erythema—Methotrexate—urinary bladder cancer	0.000259	0.000522	CcSEcCtD
Bosentan—Malnutrition—Methotrexate—urinary bladder cancer	0.000259	0.000522	CcSEcCtD
Bosentan—Haemoglobin—Doxorubicin—urinary bladder cancer	0.000259	0.000522	CcSEcCtD
Bosentan—Headache—Gemcitabine—urinary bladder cancer	0.000259	0.000522	CcSEcCtD
Bosentan—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000259	0.000521	CcSEcCtD
Bosentan—Flushing—Epirubicin—urinary bladder cancer	0.000259	0.000521	CcSEcCtD
Bosentan—Vomiting—Fluorouracil—urinary bladder cancer	0.000259	0.000521	CcSEcCtD
Bosentan—Haemorrhage—Doxorubicin—urinary bladder cancer	0.000258	0.00052	CcSEcCtD
Bosentan—Hepatitis—Doxorubicin—urinary bladder cancer	0.000258	0.00052	CcSEcCtD
Bosentan—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000257	0.000517	CcSEcCtD
Bosentan—Rash—Fluorouracil—urinary bladder cancer	0.000257	0.000517	CcSEcCtD
Bosentan—Dermatitis—Fluorouracil—urinary bladder cancer	0.000256	0.000516	CcSEcCtD
Bosentan—Headache—Fluorouracil—urinary bladder cancer	0.000255	0.000514	CcSEcCtD
Bosentan—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000255	0.000513	CcSEcCtD
Bosentan—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.000254	0.000512	CcSEcCtD
Bosentan—Asthenia—Etoposide—urinary bladder cancer	0.000254	0.000511	CcSEcCtD
Bosentan—Angiopathy—Epirubicin—urinary bladder cancer	0.000253	0.00051	CcSEcCtD
Bosentan—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000253	0.000509	CcSEcCtD
Bosentan—CYP2C9—Arachidonic acid metabolism—HPGDS—urinary bladder cancer	0.000252	0.0081	CbGpPWpGaD
Bosentan—Immune system disorder—Epirubicin—urinary bladder cancer	0.000252	0.000507	CcSEcCtD
Bosentan—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000251	0.000506	CcSEcCtD
Bosentan—Back pain—Methotrexate—urinary bladder cancer	0.000251	0.000505	CcSEcCtD
Bosentan—Chills—Epirubicin—urinary bladder cancer	0.00025	0.000504	CcSEcCtD
Bosentan—Pruritus—Etoposide—urinary bladder cancer	0.00025	0.000504	CcSEcCtD
Bosentan—Nausea—Gemcitabine—urinary bladder cancer	0.000246	0.000495	CcSEcCtD
Bosentan—Vomiting—Cisplatin—urinary bladder cancer	0.000245	0.000494	CcSEcCtD
Bosentan—Vision blurred—Methotrexate—urinary bladder cancer	0.000244	0.000492	CcSEcCtD
Bosentan—Mental disorder—Epirubicin—urinary bladder cancer	0.000244	0.000492	CcSEcCtD
Bosentan—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.000244	0.000491	CcSEcCtD
Bosentan—Rash—Cisplatin—urinary bladder cancer	0.000243	0.00049	CcSEcCtD
Bosentan—Dermatitis—Cisplatin—urinary bladder cancer	0.000243	0.000489	CcSEcCtD
Bosentan—Malnutrition—Epirubicin—urinary bladder cancer	0.000243	0.000489	CcSEcCtD
Bosentan—Erythema—Epirubicin—urinary bladder cancer	0.000243	0.000489	CcSEcCtD
Bosentan—Diarrhoea—Etoposide—urinary bladder cancer	0.000242	0.000487	CcSEcCtD
Bosentan—Nausea—Fluorouracil—urinary bladder cancer	0.000242	0.000487	CcSEcCtD
Bosentan—Eye disorder—Doxorubicin—urinary bladder cancer	0.000241	0.000486	CcSEcCtD
Bosentan—Tinnitus—Doxorubicin—urinary bladder cancer	0.000241	0.000485	CcSEcCtD
Bosentan—Anaemia—Methotrexate—urinary bladder cancer	0.00024	0.000483	CcSEcCtD
Bosentan—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000239	0.000482	CcSEcCtD
Bosentan—Flushing—Doxorubicin—urinary bladder cancer	0.000239	0.000482	CcSEcCtD
Bosentan—Flatulence—Epirubicin—urinary bladder cancer	0.000239	0.000482	CcSEcCtD
Bosentan—Back pain—Epirubicin—urinary bladder cancer	0.000235	0.000473	CcSEcCtD
Bosentan—Angiopathy—Doxorubicin—urinary bladder cancer	0.000234	0.000472	CcSEcCtD
Bosentan—Dizziness—Etoposide—urinary bladder cancer	0.000234	0.000471	CcSEcCtD
Bosentan—Muscle spasms—Epirubicin—urinary bladder cancer	0.000233	0.00047	CcSEcCtD
Bosentan—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000233	0.000469	CcSEcCtD
Bosentan—Vertigo—Methotrexate—urinary bladder cancer	0.000233	0.000469	CcSEcCtD
Bosentan—CYP3A4—Estrogen metabolism—GSTM1—urinary bladder cancer	0.000233	0.00747	CbGpPWpGaD
Bosentan—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000233	0.000468	CcSEcCtD
Bosentan—Leukopenia—Methotrexate—urinary bladder cancer	0.000232	0.000468	CcSEcCtD
Bosentan—Chills—Doxorubicin—urinary bladder cancer	0.000232	0.000466	CcSEcCtD
Bosentan—Nausea—Cisplatin—urinary bladder cancer	0.000229	0.000462	CcSEcCtD
Bosentan—Vision blurred—Epirubicin—urinary bladder cancer	0.000229	0.000461	CcSEcCtD
Bosentan—Cough—Methotrexate—urinary bladder cancer	0.000226	0.000456	CcSEcCtD
Bosentan—CYP2C9—Biological oxidations—GSTZ1—urinary bladder cancer	0.000226	0.00726	CbGpPWpGaD
Bosentan—Mental disorder—Doxorubicin—urinary bladder cancer	0.000226	0.000455	CcSEcCtD
Bosentan—Vomiting—Etoposide—urinary bladder cancer	0.000225	0.000453	CcSEcCtD
Bosentan—Erythema—Doxorubicin—urinary bladder cancer	0.000225	0.000452	CcSEcCtD
Bosentan—Malnutrition—Doxorubicin—urinary bladder cancer	0.000225	0.000452	CcSEcCtD
Bosentan—Anaemia—Epirubicin—urinary bladder cancer	0.000224	0.000452	CcSEcCtD
Bosentan—CYP2C9—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000223	0.00716	CbGpPWpGaD
Bosentan—Rash—Etoposide—urinary bladder cancer	0.000223	0.000449	CcSEcCtD
Bosentan—Dermatitis—Etoposide—urinary bladder cancer	0.000223	0.000448	CcSEcCtD
Bosentan—Headache—Etoposide—urinary bladder cancer	0.000221	0.000446	CcSEcCtD
Bosentan—Flatulence—Doxorubicin—urinary bladder cancer	0.000221	0.000446	CcSEcCtD
Bosentan—Chest pain—Methotrexate—urinary bladder cancer	0.000221	0.000445	CcSEcCtD
Bosentan—Arthralgia—Methotrexate—urinary bladder cancer	0.000221	0.000445	CcSEcCtD
Bosentan—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000219	0.000442	CcSEcCtD
Bosentan—CYP3A4—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.000219	0.00704	CbGpPWpGaD
Bosentan—CYP3A4—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.000218	0.00701	CbGpPWpGaD
Bosentan—Discomfort—Methotrexate—urinary bladder cancer	0.000218	0.000439	CcSEcCtD
Bosentan—Vertigo—Epirubicin—urinary bladder cancer	0.000218	0.000439	CcSEcCtD
Bosentan—Syncope—Epirubicin—urinary bladder cancer	0.000218	0.000438	CcSEcCtD
Bosentan—Leukopenia—Epirubicin—urinary bladder cancer	0.000217	0.000438	CcSEcCtD
Bosentan—Back pain—Doxorubicin—urinary bladder cancer	0.000217	0.000438	CcSEcCtD
Bosentan—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000216	0.000435	CcSEcCtD
Bosentan—Palpitations—Epirubicin—urinary bladder cancer	0.000215	0.000432	CcSEcCtD
Bosentan—CYP2C9—Biological oxidations—GSTO2—urinary bladder cancer	0.000214	0.00688	CbGpPWpGaD
Bosentan—CYP2C9—Biological oxidations—NAT1—urinary bladder cancer	0.000214	0.00688	CbGpPWpGaD
Bosentan—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000213	0.00043	CcSEcCtD
Bosentan—Cough—Epirubicin—urinary bladder cancer	0.000212	0.000427	CcSEcCtD
Bosentan—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000212	0.000426	CcSEcCtD
Bosentan—Vision blurred—Doxorubicin—urinary bladder cancer	0.000212	0.000426	CcSEcCtD
Bosentan—CYP2C9—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000211	0.00679	CbGpPWpGaD
Bosentan—Infection—Methotrexate—urinary bladder cancer	0.00021	0.000424	CcSEcCtD
Bosentan—Nausea—Etoposide—urinary bladder cancer	0.00021	0.000423	CcSEcCtD
Bosentan—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000208	0.000418	CcSEcCtD
Bosentan—Anaemia—Doxorubicin—urinary bladder cancer	0.000208	0.000418	CcSEcCtD
Bosentan—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000207	0.000417	CcSEcCtD
Bosentan—Chest pain—Epirubicin—urinary bladder cancer	0.000207	0.000416	CcSEcCtD
Bosentan—Arthralgia—Epirubicin—urinary bladder cancer	0.000207	0.000416	CcSEcCtD
Bosentan—Anxiety—Epirubicin—urinary bladder cancer	0.000206	0.000415	CcSEcCtD
Bosentan—Skin disorder—Methotrexate—urinary bladder cancer	0.000206	0.000414	CcSEcCtD
Bosentan—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000205	0.000413	CcSEcCtD
Bosentan—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000205	0.000412	CcSEcCtD
Bosentan—Discomfort—Epirubicin—urinary bladder cancer	0.000204	0.000411	CcSEcCtD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000203	0.00652	CbGpPWpGaD
Bosentan—Dry mouth—Epirubicin—urinary bladder cancer	0.000202	0.000407	CcSEcCtD
Bosentan—Vertigo—Doxorubicin—urinary bladder cancer	0.000202	0.000406	CcSEcCtD
Bosentan—Anorexia—Methotrexate—urinary bladder cancer	0.000202	0.000406	CcSEcCtD
Bosentan—Syncope—Doxorubicin—urinary bladder cancer	0.000201	0.000406	CcSEcCtD
Bosentan—Leukopenia—Doxorubicin—urinary bladder cancer	0.000201	0.000405	CcSEcCtD
Bosentan—Palpitations—Doxorubicin—urinary bladder cancer	0.000199	0.0004	CcSEcCtD
Bosentan—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000198	0.000399	CcSEcCtD
Bosentan—Oedema—Epirubicin—urinary bladder cancer	0.000198	0.000399	CcSEcCtD
Bosentan—Hypotension—Methotrexate—urinary bladder cancer	0.000198	0.000398	CcSEcCtD
Bosentan—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000197	0.000398	CcSEcCtD
Bosentan—Infection—Epirubicin—urinary bladder cancer	0.000197	0.000396	CcSEcCtD
Bosentan—CYP2C9—Biological oxidations—UGT2B7—urinary bladder cancer	0.000196	0.00629	CbGpPWpGaD
Bosentan—Cough—Doxorubicin—urinary bladder cancer	0.000196	0.000395	CcSEcCtD
Bosentan—Shock—Epirubicin—urinary bladder cancer	0.000195	0.000393	CcSEcCtD
Bosentan—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000194	0.000391	CcSEcCtD
Bosentan—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000194	0.000391	CcSEcCtD
Bosentan—CYP2C9—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000193	0.00621	CbGpPWpGaD
Bosentan—Tachycardia—Epirubicin—urinary bladder cancer	0.000193	0.000389	CcSEcCtD
Bosentan—EDNRA—Endothelins—HRAS—urinary bladder cancer	0.000193	0.0062	CbGpPWpGaD
Bosentan—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000193	0.000388	CcSEcCtD
Bosentan—Skin disorder—Epirubicin—urinary bladder cancer	0.000192	0.000388	CcSEcCtD
Bosentan—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000192	0.000386	CcSEcCtD
Bosentan—Insomnia—Methotrexate—urinary bladder cancer	0.000191	0.000386	CcSEcCtD
Bosentan—Arthralgia—Doxorubicin—urinary bladder cancer	0.000191	0.000385	CcSEcCtD
Bosentan—Chest pain—Doxorubicin—urinary bladder cancer	0.000191	0.000385	CcSEcCtD
Bosentan—Anxiety—Doxorubicin—urinary bladder cancer	0.000191	0.000384	CcSEcCtD
Bosentan—EDNRB—Peptide ligand-binding receptors—CXCL8—urinary bladder cancer	0.00019	0.00611	CbGpPWpGaD
Bosentan—Paraesthesia—Methotrexate—urinary bladder cancer	0.00019	0.000383	CcSEcCtD
Bosentan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.00019	0.000383	CcSEcCtD
Bosentan—Discomfort—Doxorubicin—urinary bladder cancer	0.000189	0.000381	CcSEcCtD
Bosentan—Anorexia—Epirubicin—urinary bladder cancer	0.000189	0.00038	CcSEcCtD
Bosentan—Dyspnoea—Methotrexate—urinary bladder cancer	0.000189	0.00038	CcSEcCtD
Bosentan—Somnolence—Methotrexate—urinary bladder cancer	0.000188	0.000379	CcSEcCtD
Bosentan—Dry mouth—Doxorubicin—urinary bladder cancer	0.000187	0.000377	CcSEcCtD
Bosentan—Dyspepsia—Methotrexate—urinary bladder cancer	0.000186	0.000375	CcSEcCtD
Bosentan—Hypotension—Epirubicin—urinary bladder cancer	0.000185	0.000373	CcSEcCtD
Bosentan—Decreased appetite—Methotrexate—urinary bladder cancer	0.000184	0.000371	CcSEcCtD
Bosentan—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000183	0.000369	CcSEcCtD
Bosentan—Oedema—Doxorubicin—urinary bladder cancer	0.000183	0.000369	CcSEcCtD
Bosentan—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000183	0.000368	CcSEcCtD
Bosentan—Fatigue—Methotrexate—urinary bladder cancer	0.000183	0.000368	CcSEcCtD
Bosentan—Infection—Doxorubicin—urinary bladder cancer	0.000182	0.000367	CcSEcCtD
Bosentan—Pain—Methotrexate—urinary bladder cancer	0.000181	0.000365	CcSEcCtD
Bosentan—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000181	0.000364	CcSEcCtD
Bosentan—Shock—Doxorubicin—urinary bladder cancer	0.00018	0.000363	CcSEcCtD
Bosentan—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.00018	0.000362	CcSEcCtD
Bosentan—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000179	0.000362	CcSEcCtD
Bosentan—Insomnia—Epirubicin—urinary bladder cancer	0.000179	0.000361	CcSEcCtD
Bosentan—Tachycardia—Doxorubicin—urinary bladder cancer	0.000179	0.00036	CcSEcCtD
Bosentan—Skin disorder—Doxorubicin—urinary bladder cancer	0.000178	0.000359	CcSEcCtD
Bosentan—Paraesthesia—Epirubicin—urinary bladder cancer	0.000178	0.000358	CcSEcCtD
Bosentan—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000177	0.000357	CcSEcCtD
Bosentan—Dyspnoea—Epirubicin—urinary bladder cancer	0.000177	0.000356	CcSEcCtD
Bosentan—CYP2C9—Biological oxidations—CYP4B1—urinary bladder cancer	0.000177	0.00567	CbGpPWpGaD
Bosentan—Somnolence—Epirubicin—urinary bladder cancer	0.000176	0.000355	CcSEcCtD
Bosentan—Anorexia—Doxorubicin—urinary bladder cancer	0.000175	0.000352	CcSEcCtD
Bosentan—Dyspepsia—Epirubicin—urinary bladder cancer	0.000174	0.000351	CcSEcCtD
Bosentan—CYP2C9—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000174	0.00559	CbGpPWpGaD
Bosentan—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000173	0.000349	CcSEcCtD
Bosentan—Decreased appetite—Epirubicin—urinary bladder cancer	0.000172	0.000347	CcSEcCtD
Bosentan—Hypotension—Doxorubicin—urinary bladder cancer	0.000171	0.000345	CcSEcCtD
Bosentan—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000171	0.000345	CcSEcCtD
Bosentan—Fatigue—Epirubicin—urinary bladder cancer	0.000171	0.000344	CcSEcCtD
Bosentan—Pain—Epirubicin—urinary bladder cancer	0.000169	0.000341	CcSEcCtD
Bosentan—Constipation—Epirubicin—urinary bladder cancer	0.000169	0.000341	CcSEcCtD
Bosentan—Urticaria—Methotrexate—urinary bladder cancer	0.000168	0.000339	CcSEcCtD
Bosentan—Abdominal pain—Methotrexate—urinary bladder cancer	0.000167	0.000337	CcSEcCtD
Bosentan—Body temperature increased—Methotrexate—urinary bladder cancer	0.000167	0.000337	CcSEcCtD
Bosentan—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000167	0.000336	CcSEcCtD
Bosentan—Insomnia—Doxorubicin—urinary bladder cancer	0.000166	0.000334	CcSEcCtD
Bosentan—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000165	0.000332	CcSEcCtD
Bosentan—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000163	0.000329	CcSEcCtD
Bosentan—Somnolence—Doxorubicin—urinary bladder cancer	0.000163	0.000328	CcSEcCtD
Bosentan—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000162	0.000326	CcSEcCtD
Bosentan—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000161	0.000325	CcSEcCtD
Bosentan—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000159	0.000321	CcSEcCtD
Bosentan—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000158	0.000319	CcSEcCtD
Bosentan—Fatigue—Doxorubicin—urinary bladder cancer	0.000158	0.000318	CcSEcCtD
Bosentan—Urticaria—Epirubicin—urinary bladder cancer	0.000157	0.000317	CcSEcCtD
Bosentan—Constipation—Doxorubicin—urinary bladder cancer	0.000157	0.000316	CcSEcCtD
Bosentan—Pain—Doxorubicin—urinary bladder cancer	0.000157	0.000316	CcSEcCtD
Bosentan—Abdominal pain—Epirubicin—urinary bladder cancer	0.000157	0.000315	CcSEcCtD
Bosentan—Body temperature increased—Epirubicin—urinary bladder cancer	0.000157	0.000315	CcSEcCtD
Bosentan—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000156	0.000314	CcSEcCtD
Bosentan—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000152	0.00488	CbGpPWpGaD
Bosentan—Asthenia—Methotrexate—urinary bladder cancer	0.000152	0.000306	CcSEcCtD
Bosentan—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.00015	0.000302	CcSEcCtD
Bosentan—Pruritus—Methotrexate—urinary bladder cancer	0.00015	0.000302	CcSEcCtD
Bosentan—CYP2C9—Arachidonic acid metabolism—GPX1—urinary bladder cancer	0.000149	0.00479	CbGpPWpGaD
Bosentan—CYP3A4—Biological oxidations—GSTZ1—urinary bladder cancer	0.000149	0.00479	CbGpPWpGaD
Bosentan—CYP3A4—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000147	0.00472	CbGpPWpGaD
Bosentan—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000146	0.000294	CcSEcCtD
Bosentan—Urticaria—Doxorubicin—urinary bladder cancer	0.000146	0.000293	CcSEcCtD
Bosentan—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000145	0.000292	CcSEcCtD
Bosentan—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000145	0.000292	CcSEcCtD
Bosentan—Diarrhoea—Methotrexate—urinary bladder cancer	0.000145	0.000292	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—HDAC4—urinary bladder cancer	0.000144	0.00462	CbGpPWpGaD
Bosentan—Asthenia—Epirubicin—urinary bladder cancer	0.000142	0.000286	CcSEcCtD
Bosentan—CYP3A4—Biological oxidations—GSTO2—urinary bladder cancer	0.000141	0.00454	CbGpPWpGaD
Bosentan—CYP3A4—Biological oxidations—NAT1—urinary bladder cancer	0.000141	0.00454	CbGpPWpGaD
Bosentan—Pruritus—Epirubicin—urinary bladder cancer	0.00014	0.000282	CcSEcCtD
Bosentan—Dizziness—Methotrexate—urinary bladder cancer	0.00014	0.000282	CcSEcCtD
Bosentan—CYP3A4—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000139	0.00448	CbGpPWpGaD
Bosentan—EDNRA—Peptide ligand-binding receptors—CXCL8—urinary bladder cancer	0.000136	0.00437	CbGpPWpGaD
Bosentan—Diarrhoea—Epirubicin—urinary bladder cancer	0.000136	0.000273	CcSEcCtD
Bosentan—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000135	0.000272	CcSEcCtD
Bosentan—Vomiting—Methotrexate—urinary bladder cancer	0.000135	0.000271	CcSEcCtD
Bosentan—Rash—Methotrexate—urinary bladder cancer	0.000133	0.000269	CcSEcCtD
Bosentan—Dermatitis—Methotrexate—urinary bladder cancer	0.000133	0.000269	CcSEcCtD
Bosentan—Headache—Methotrexate—urinary bladder cancer	0.000133	0.000267	CcSEcCtD
Bosentan—Asthenia—Doxorubicin—urinary bladder cancer	0.000132	0.000265	CcSEcCtD
Bosentan—Dizziness—Epirubicin—urinary bladder cancer	0.000131	0.000264	CcSEcCtD
Bosentan—Pruritus—Doxorubicin—urinary bladder cancer	0.00013	0.000261	CcSEcCtD
Bosentan—CYP3A4—Biological oxidations—UGT2B7—urinary bladder cancer	0.000129	0.00415	CbGpPWpGaD
Bosentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	0.000128	0.0041	CbGpPWpGaD
Bosentan—CYP3A4—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000128	0.00409	CbGpPWpGaD
Bosentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—urinary bladder cancer	0.000126	0.00404	CbGpPWpGaD
Bosentan—Vomiting—Epirubicin—urinary bladder cancer	0.000126	0.000254	CcSEcCtD
Bosentan—Nausea—Methotrexate—urinary bladder cancer	0.000126	0.000253	CcSEcCtD
Bosentan—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000125	0.000253	CcSEcCtD
Bosentan—Rash—Epirubicin—urinary bladder cancer	0.000125	0.000252	CcSEcCtD
Bosentan—Dermatitis—Epirubicin—urinary bladder cancer	0.000125	0.000251	CcSEcCtD
Bosentan—Headache—Epirubicin—urinary bladder cancer	0.000124	0.00025	CcSEcCtD
Bosentan—Dizziness—Doxorubicin—urinary bladder cancer	0.000121	0.000244	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—GLI1—urinary bladder cancer	0.000121	0.00387	CbGpPWpGaD
Bosentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—urinary bladder cancer	0.000119	0.00382	CbGpPWpGaD
Bosentan—Nausea—Epirubicin—urinary bladder cancer	0.000118	0.000237	CcSEcCtD
Bosentan—CYP2C9—Biological oxidations—NAT2—urinary bladder cancer	0.000117	0.00377	CbGpPWpGaD
Bosentan—Vomiting—Doxorubicin—urinary bladder cancer	0.000117	0.000235	CcSEcCtD
Bosentan—CYP3A4—Biological oxidations—CYP4B1—urinary bladder cancer	0.000116	0.00374	CbGpPWpGaD
Bosentan—CYP2C9—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000116	0.00372	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—GSTZ1—urinary bladder cancer	0.000116	0.00372	CbGpPWpGaD
Bosentan—Rash—Doxorubicin—urinary bladder cancer	0.000116	0.000233	CcSEcCtD
Bosentan—Dermatitis—Doxorubicin—urinary bladder cancer	0.000115	0.000233	CcSEcCtD
Bosentan—CYP3A4—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000115	0.00369	CbGpPWpGaD
Bosentan—Headache—Doxorubicin—urinary bladder cancer	0.000115	0.000231	CcSEcCtD
Bosentan—ABCB11—Metabolism—NAT1—urinary bladder cancer	0.00011	0.00352	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—GSTO2—urinary bladder cancer	0.00011	0.00352	CbGpPWpGaD
Bosentan—Nausea—Doxorubicin—urinary bladder cancer	0.000109	0.000219	CcSEcCtD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	0.000108	0.00347	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—HDAC4—urinary bladder cancer	0.000103	0.00331	CbGpPWpGaD
Bosentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—urinary bladder cancer	0.000101	0.00325	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—UGT2B7—urinary bladder cancer	0.0001	0.00322	CbGpPWpGaD
Bosentan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.0001	0.00322	CbGpPWpGaD
Bosentan—EDNRB—GPCR ligand binding—CXCL8—urinary bladder cancer	9.72e-05	0.00312	CbGpPWpGaD
Bosentan—CYP2C9—Biological oxidations—HPGDS—urinary bladder cancer	9.39e-05	0.00301	CbGpPWpGaD
Bosentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	9.13e-05	0.00293	CbGpPWpGaD
Bosentan—CYP2C9—Biological oxidations—GSTT1—urinary bladder cancer	9.11e-05	0.00292	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—CYP4B1—urinary bladder cancer	9.04e-05	0.0029	CbGpPWpGaD
Bosentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—urinary bladder cancer	9.02e-05	0.00289	CbGpPWpGaD
Bosentan—CYP2C9—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	8.79e-05	0.00282	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—GLI1—urinary bladder cancer	8.63e-05	0.00277	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—SLC19A1—urinary bladder cancer	8.54e-05	0.00274	CbGpPWpGaD
Bosentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—urinary bladder cancer	8.52e-05	0.00273	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—PRSS3—urinary bladder cancer	8.32e-05	0.00267	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—RBX1—urinary bladder cancer	8.27e-05	0.00265	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—TSC1—urinary bladder cancer	7.77e-05	0.00249	CbGpPWpGaD
Bosentan—CYP3A4—Biological oxidations—NAT2—urinary bladder cancer	7.75e-05	0.00249	CbGpPWpGaD
Bosentan—CYP3A4—Metapathway biotransformation—NAT2—urinary bladder cancer	7.64e-05	0.00245	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—JAG1—urinary bladder cancer	7.4e-05	0.00238	CbGpPWpGaD
Bosentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—urinary bladder cancer	7.24e-05	0.00232	CbGpPWpGaD
Bosentan—EDNRA—GPCR ligand binding—CXCL8—urinary bladder cancer	6.96e-05	0.00223	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	6.78e-05	0.00218	CbGpPWpGaD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	6.67e-05	0.00214	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—TYMP—urinary bladder cancer	6.65e-05	0.00214	CbGpPWpGaD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	6.39e-05	0.00205	CbGpPWpGaD
Bosentan—CYP2C9—Biological oxidations—GSTP1—urinary bladder cancer	6.31e-05	0.00203	CbGpPWpGaD
Bosentan—EDNRB—GPCR downstream signaling—RHOA—urinary bladder cancer	6.26e-05	0.00201	CbGpPWpGaD
Bosentan—CYP2C9—Metapathway biotransformation—GSTP1—urinary bladder cancer	6.23e-05	0.002	CbGpPWpGaD
Bosentan—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	6.19e-05	0.00199	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—NAT2—urinary bladder cancer	6.02e-05	0.00193	CbGpPWpGaD
Bosentan—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	6.01e-05	0.00193	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—S100B—urinary bladder cancer	5.99e-05	0.00192	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—RBX1—urinary bladder cancer	5.92e-05	0.0019	CbGpPWpGaD
Bosentan—CYP2C9—Biological oxidations—GSTM1—urinary bladder cancer	5.8e-05	0.00186	CbGpPWpGaD
Bosentan—CYP2C9—Metapathway biotransformation—GSTM1—urinary bladder cancer	5.72e-05	0.00184	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—RHOA—urinary bladder cancer	5.68e-05	0.00182	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—TSC1—urinary bladder cancer	5.56e-05	0.00179	CbGpPWpGaD
Bosentan—EDNRB—GPCR downstream signaling—CXCL8—urinary bladder cancer	5.49e-05	0.00176	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—NCOR1—urinary bladder cancer	5.39e-05	0.00173	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—JAG1—urinary bladder cancer	5.3e-05	0.0017	CbGpPWpGaD
Bosentan—EDNRB—GPCR downstream signaling—IL2—urinary bladder cancer	5.25e-05	0.00168	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—RRM2—urinary bladder cancer	5.19e-05	0.00167	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—CXCL8—urinary bladder cancer	4.99e-05	0.0016	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—HPGDS—urinary bladder cancer	4.81e-05	0.00154	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—ENO2—urinary bladder cancer	4.81e-05	0.00154	CbGpPWpGaD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	4.78e-05	0.00153	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—IL2—urinary bladder cancer	4.77e-05	0.00153	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—TERT—urinary bladder cancer	4.75e-05	0.00152	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—GSTT1—urinary bladder cancer	4.67e-05	0.0015	CbGpPWpGaD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	4.59e-05	0.00147	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—RHOA—urinary bladder cancer	4.48e-05	0.00144	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—FGFR3—urinary bladder cancer	4.36e-05	0.0014	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—S100B—urinary bladder cancer	4.29e-05	0.00138	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—ESR1—urinary bladder cancer	4.23e-05	0.00136	CbGpPWpGaD
Bosentan—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	4.16e-05	0.00134	CbGpPWpGaD
Bosentan—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	4.11e-05	0.00132	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—RHOA—urinary bladder cancer	4.07e-05	0.0013	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—CXCL8—urinary bladder cancer	3.93e-05	0.00126	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—NQO1—urinary bladder cancer	3.88e-05	0.00124	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—GSTZ1—urinary bladder cancer	3.87e-05	0.00124	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—NCOR1—urinary bladder cancer	3.86e-05	0.00124	CbGpPWpGaD
Bosentan—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	3.83e-05	0.00123	CbGpPWpGaD
Bosentan—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	3.77e-05	0.00121	CbGpPWpGaD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	3.76e-05	0.00121	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—IL2—urinary bladder cancer	3.76e-05	0.00121	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—CREBBP—urinary bladder cancer	3.71e-05	0.00119	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—GSTO2—urinary bladder cancer	3.67e-05	0.00118	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—NAT1—urinary bladder cancer	3.67e-05	0.00118	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—IGF1—urinary bladder cancer	3.66e-05	0.00118	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—EGFR—urinary bladder cancer	3.65e-05	0.00117	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	3.61e-05	0.00116	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—CXCL8—urinary bladder cancer	3.57e-05	0.00115	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—KRAS—urinary bladder cancer	3.44e-05	0.00111	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—IL2—urinary bladder cancer	3.41e-05	0.00109	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—TERT—urinary bladder cancer	3.4e-05	0.00109	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—RHOA—urinary bladder cancer	3.36e-05	0.00108	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—UGT2B7—urinary bladder cancer	3.35e-05	0.00108	CbGpPWpGaD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	3.28e-05	0.00105	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—GSTP1—urinary bladder cancer	3.23e-05	0.00104	CbGpPWpGaD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	3.13e-05	0.001	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—FGFR3—urinary bladder cancer	3.12e-05	0.001	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—ERBB2—urinary bladder cancer	3.11e-05	0.000997	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—ESR1—urinary bladder cancer	3.03e-05	0.000972	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—CYP4B1—urinary bladder cancer	3.02e-05	0.000969	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—TYMS—urinary bladder cancer	3.01e-05	0.000965	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—NCOR1—urinary bladder cancer	2.97e-05	0.000954	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—GSTM1—urinary bladder cancer	2.97e-05	0.000954	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—CXCL8—urinary bladder cancer	2.95e-05	0.000946	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—HRAS—urinary bladder cancer	2.93e-05	0.000939	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—SLC19A1—urinary bladder cancer	2.85e-05	0.000915	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—GPX1—urinary bladder cancer	2.85e-05	0.000913	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—IL2—urinary bladder cancer	2.82e-05	0.000904	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—ERCC2—urinary bladder cancer	2.79e-05	0.000897	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—PRSS3—urinary bladder cancer	2.78e-05	0.000892	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—CCND1—urinary bladder cancer	2.74e-05	0.000881	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—MMP9—urinary bladder cancer	2.66e-05	0.000855	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—CDKN1A—urinary bladder cancer	2.66e-05	0.000852	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—CREBBP—urinary bladder cancer	2.66e-05	0.000852	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—PTEN—urinary bladder cancer	2.65e-05	0.00085	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—MTHFR—urinary bladder cancer	2.63e-05	0.000843	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—IGF1—urinary bladder cancer	2.62e-05	0.000841	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—EGFR—urinary bladder cancer	2.61e-05	0.000837	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	2.55e-05	0.000819	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—EP300—urinary bladder cancer	2.53e-05	0.000811	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—KRAS—urinary bladder cancer	2.46e-05	0.000791	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—SRC—urinary bladder cancer	2.46e-05	0.000788	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	2.42e-05	0.000776	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—NAT1—urinary bladder cancer	2.42e-05	0.000776	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—RHOA—urinary bladder cancer	2.4e-05	0.000771	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	2.23e-05	0.000715	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—ERBB2—urinary bladder cancer	2.22e-05	0.000714	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—TYMP—urinary bladder cancer	2.22e-05	0.000713	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	2.21e-05	0.00071	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—MYC—urinary bladder cancer	2.2e-05	0.000707	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—EGFR—urinary bladder cancer	2.15e-05	0.000691	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	2.13e-05	0.000685	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—PPARG—urinary bladder cancer	2.13e-05	0.000684	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—CXCL8—urinary bladder cancer	2.11e-05	0.000677	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—HRAS—urinary bladder cancer	2.09e-05	0.000672	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—CREBBP—urinary bladder cancer	2.05e-05	0.000657	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—KRAS—urinary bladder cancer	2.03e-05	0.000653	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—IL2—urinary bladder cancer	2.02e-05	0.000647	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—NAT2—urinary bladder cancer	2.01e-05	0.000645	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	1.99e-05	0.000639	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—CCND1—urinary bladder cancer	1.96e-05	0.00063	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—MMP9—urinary bladder cancer	1.91e-05	0.000612	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—CDKN1A—urinary bladder cancer	1.9e-05	0.00061	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—PTEN—urinary bladder cancer	1.9e-05	0.000608	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	1.88e-05	0.000604	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	1.83e-05	0.000588	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—EP300—urinary bladder cancer	1.81e-05	0.00058	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—TP53—urinary bladder cancer	1.81e-05	0.00058	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—SRC—urinary bladder cancer	1.76e-05	0.000564	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—RRM2—urinary bladder cancer	1.73e-05	0.000557	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—HRAS—urinary bladder cancer	1.73e-05	0.000555	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—PTGS2—urinary bladder cancer	1.68e-05	0.000538	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—ENO2—urinary bladder cancer	1.61e-05	0.000515	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	1.61e-05	0.000515	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.6e-05	0.000512	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—MYC—urinary bladder cancer	1.58e-05	0.000506	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	1.56e-05	0.0005	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—EGFR—urinary bladder cancer	1.54e-05	0.000495	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.53e-05	0.000492	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—TYMP—urinary bladder cancer	1.47e-05	0.00047	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—PTEN—urinary bladder cancer	1.46e-05	0.000469	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—KRAS—urinary bladder cancer	1.46e-05	0.000467	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—EP300—urinary bladder cancer	1.39e-05	0.000447	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—NAT2—urinary bladder cancer	1.33e-05	0.000425	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—NQO1—urinary bladder cancer	1.29e-05	0.000415	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—TP53—urinary bladder cancer	1.29e-05	0.000415	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.26e-05	0.000403	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—HRAS—urinary bladder cancer	1.24e-05	0.000397	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—RRM2—urinary bladder cancer	1.14e-05	0.000367	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.1e-05	0.000352	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	1.08e-05	0.000347	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	1.06e-05	0.00034	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—ENO2—urinary bladder cancer	1.06e-05	0.00034	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.04e-05	0.000335	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	1.03e-05	0.00033	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—TYMS—urinary bladder cancer	1e-05	0.000322	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	9.92e-06	0.000318	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	9.92e-06	0.000318	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—GPX1—urinary bladder cancer	9.5e-06	0.000305	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	9.33e-06	0.000299	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	8.77e-06	0.000281	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—NQO1—urinary bladder cancer	8.54e-06	0.000274	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	7.12e-06	0.000229	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—PPARG—urinary bladder cancer	7.11e-06	0.000228	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	6.83e-06	0.000219	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—TYMS—urinary bladder cancer	6.62e-06	0.000212	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	6.54e-06	0.00021	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	6.54e-06	0.00021	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—GPX1—urinary bladder cancer	6.27e-06	0.000201	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	6.15e-06	0.000197	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	5.78e-06	0.000186	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	5.59e-06	0.00018	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—PTEN—urinary bladder cancer	4.88e-06	0.000157	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—PPARG—urinary bladder cancer	4.69e-06	0.000151	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—EP300—urinary bladder cancer	4.65e-06	0.000149	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	4.51e-06	0.000145	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	3.69e-06	0.000118	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—PTEN—urinary bladder cancer	3.22e-06	0.000103	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—EP300—urinary bladder cancer	3.07e-06	9.85e-05	CbGpPWpGaD
